CD248 and neoplasm: (2014) targeted TEM-1/endosialin, a marker which is aberrantly expressed on tumor-associated endothelium and in tumor stroma, with a fusion DNA vaccine comprising mouse Tem-1 cDNA attached to the C-terminal end region of TTX (93).